Deepti Jacob, MD
Gastroenterology · Omaha, NENPI 1770933632
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,228, 4.7 times the $261 reported in 2022.
Across 177 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$543
- AbbVie$483
- Madrigal Pharmaceuticals$351
- Regeneron Healthcare Solutions, Inc.$279
- Sanofi$225
- Takeda Pharmaceuticals U.S.A., Inc.$217
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,22099%
- Education$201%
- Other$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 33 | $543 |
| AbbVie | 31 | $483 |
| Madrigal Pharmaceuticals | 18 | $351 |
| Regeneron Healthcare Solutions, Inc. | 14 | $279 |
| Sanofi | 9 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $217 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $200 |
| Gilead | 10 | $189 |
| Bristol Myers Squibb | 10 | $186 |
| Ironwood Pharmaceuticals, Inc | 7 | $146 |
| Ardelyx, Inc. | 5 | $98 |
| Aimmune Therapeutics, Inc. | 1 | $84 |
| Lilly USA, LLC | 3 | $60 |
| Phathom Pharmaceuticals, Inc. | 6 | $40 |
| Intercept Pharmaceuticals, Inc. | 2 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Organon | 1 | $18 |
| Celltrion USA Inc. | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| QOL Medical, LLC | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
How this compares
$3,253 in reported general payments places this provider in the 55th percentile of 89 gastroenterology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 143 | $2,887 |
| Pantoprazole Sodium | 115 | $1,337 |
| Mesalamine ErMesalamine | 12 | $1,041 |
| Omeprazole | 58 | $938 |
| Colestipol Hcl | 15 | $813 |
| Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg | 18 | $308 |
| Sucralfate | 11 | $275 |
| Famotidine | 11 | $52 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Omaha
- Benjamin HallOmaha$154K
- Sandeep MukherjeeOmaha$145K
- Rowen ZettermanOmaha$119K
- Derrick EicheleOmaha$54K
- Joshua EvansOmaha$34K
- Michael SchaferOmaha$30K
- Peter MannonOmaha$30K
- Helen Fasanya-UptagraftOmaha$26K
- Rajani RangrayOmaha$15K
- Grant HutchinsOmaha$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.